XML 59 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
License and Acquisition Agreements - Regeneron License Agreement (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Sep. 30, 2017
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
License and Acquisition Agreements        
Research and development   $ 26,334 $ 15,172  
Uncured period which causes termination of the agreement, due to insolvency or bankruptcy or for material breach of the agreement by the other party that remains uncured 90 days      
Notice period to terminate the agreement under payment-related breaches 30 days      
Consecutive suspension of activities period for termination of agreement 12 months      
Notice period to terminate the agreement 1 year      
Notice period to terminate the agreement if products are having safety concerns 3 months      
Commercial product inventory   27,278   $ 31,122
Regulatory milestone        
License and Acquisition Agreements        
Intangible asset - Regulatory milestone   20,000   20,000
Regeneron | License Agreement        
License and Acquisition Agreements        
Profit sharing recognized   20,123 8,288  
Regeneron | Clinical Supply Agreement        
License and Acquisition Agreements        
Research and development   0 $ 0  
Commercial product inventory   $ 26,252   $ 31,122